FY2027 Earnings Forecast for Ardelyx Issued By HC Wainwright

Ardelyx, Inc. (NASDAQ:ARDX) – HC Wainwright decreased their FY2027 earnings per share estimates for Ardelyx in a report released on Friday, August 7th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings of $0.35 per share for the year, down from their prior forecast of $0.36. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.10) per share. HC Wainwright also issued estimates for Ardelyx’s FY2028 earnings at $0.66 EPS.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative return on equity of 35.57% and a negative net margin of 12.35%.The company’s revenue was up 34.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.08) EPS.

A number of other brokerages have also commented on ARDX. Weiss Ratings lowered shares of Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. LADENBURG THALM/SH SH assumed coverage on Ardelyx in a report on Tuesday, June 16th. They issued a “buy” rating and a $16.00 price target for the company. BTIG Research reduced their price objective on Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday. TD Cowen decreased their price objective on Ardelyx from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Friday. Finally, Zacks Research cut Ardelyx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Ardelyx Price Performance

Shares of Ardelyx stock opened at $4.00 on Monday. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.49 and a quick ratio of 3.28. The company has a market cap of $996.76 million, a PE ratio of -18.18 and a beta of 0.70. The firm has a fifty day moving average price of $5.34 and a two-hundred day moving average price of $6.04. Ardelyx has a fifty-two week low of $3.90 and a fifty-two week high of $8.40.

Insider Transactions at Ardelyx

In other Ardelyx news, insider Mike Kelliher sold 7,248 shares of Ardelyx stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $45,444.96. Following the sale, the insider directly owned 357,418 shares of the company’s stock, valued at approximately $2,241,010.86. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Duane Foster sold 7,998 shares of the business’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total value of $50,147.46. Following the completion of the sale, the insider directly owned 417,972 shares in the company, valued at approximately $2,620,684.44. This represents a 1.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 24,572 shares of company stock valued at $154,066. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

Large investors have recently made changes to their positions in the company. First Horizon Corp lifted its holdings in Ardelyx by 120.4% during the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 4,319 shares during the last quarter. SCS Capital Management LLC bought a new stake in Ardelyx during the second quarter worth about $52,000. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Ardelyx during the fourth quarter worth approximately $60,000. State of Wyoming acquired a new stake in shares of Ardelyx during the second quarter worth approximately $61,000. Finally, PVG Asset Management Corp bought a new position in shares of Ardelyx in the first quarter valued at approximately $65,000. Institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.